Avalo Therapeutics lowers stockholder meeting quorum from majority to one-third

Avalo Therapeutics, Inc.

Board approved Fourth Amended and Restated Bylaws on October 16, 2023, effective immediately.
Quorum reduced to one-third of shares entitled to vote, present in person or by proxy.
Previous requirement was a majority of shares present in person or by proxy.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Avalo Therapeutics, Inc.: Amended quorum requirement for stockholder meetings from majority of shares present to one-third of shares entitled to vote (effective 2023-10-16).

Change: bylaw amendment
Effective: 2023-10-16

Exact text from the filing

On October 16, 2023, the Board of Directors of Avalo Therapeutics, Inc. (the “Company”) approved the Company’s Fourth Amended and Restated Bylaws, effective immediately upon approval by the Board (the “Amended and Restated Bylaws”).

View on SEC.gov

Browse all governance changes →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-034510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.